Longeveron Phase 2b trial reports stem cell therapy improved condition in age-related frailty.

A Phase 2b randomized trial of Longeveron's laromestrocel, published in Cell Stem Cell, reported improved physical condition in 148 ambulatory patients with age-related frailty at nine months versus placebo.

Longeveron announced that results from its Phase 2b clinical trial were published in Cell Stem Cell. The trial tested intravenous laromestrocel, an allogeneic mesenchymal stem cell product, in ambulatory adults with age-related clinical frailty. The randomized, dose-finding study enrolled 148 participants and measured physical functioning and patient self-reported outcomes. The published report states that laromestrocel infusions improved participants' physical condition at nine months compared with placebo. Key findings: - The publication appeared in Cell Stem Cell and was announced on February 25, 2026. - The study was a Phase 2b randomized, dose-finding trial registered as NCT03169231 with 148 ambulatory individuals with frailty. - The investigational product tested was laromestrocel (LOMECEL-B), a human bone marrow-derived allogeneic mesenchymal stem cell therapy. - The trial assessed physical functioning and patient-reported outcomes and reported improved physical condition at nine months versus placebo. - The article describes these findings as identifying a possible stem cell therapy approach for managing hypomobility and other features of aging frailty. Summary: The publication reports that laromestrocel was associated with improved physical condition in the studied population and frames the results as a potential approach for managing aspects of aging frailty. Undetermined at this time.